Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer immunotherapies. The company has four clinical-stage product candidates: AB928, which is an orally bioavailable, reversible antagonist of the adenosine 2a and adenosine 2b receptors; AB680, which is a reversible and selective inhibitor of the CD73 enzyme; AB122, which is a human antibody with similar binding affinity and other characteristics to the marketed anti-PD-1 antibodies pembrolizumab and nivolumab; and AB154, which is a humanized antibody that inhibits an immune checkpoint target involved in a pathway that plays both inhibitory and stimulatory roles in the immune system.
  • TickerRCUS
  • ISINUS03969F1093
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
  • Robert Driscoll

ESMO 2019 Roundup for Covered Companies

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
  • Robert Driscoll

ESMO 2019 Roundup for Covered Companies

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ResearchPool Subscriptions

Get the most out of your insights

Get in touch